Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentSelling, General & AdministrativeShares OutstandingShares Outstanding (Weighted Average)
Others
Ratios

Viking Therapeutics (VKTX) EBITDA (2016 - 2025)

Viking Therapeutics' EBITDA history spans 12 years, with the latest figure at -$157.7 million for Q4 2025.

  • For Q4 2025, EBITDA fell 316.68% year-over-year to -$157.7 million; the TTM value through Dec 2025 reached -$358.5 million, down 224.82%, while the annual FY2025 figure was -$358.5 million, 224.82% down from the prior year.
  • EBITDA for Q4 2025 was -$157.7 million at Viking Therapeutics, down from -$90.2 million in the prior quarter.
  • Across five years, EBITDA topped out at -$12.7 million in Q4 2021 and bottomed at -$157.7 million in Q4 2025.
  • The 5-year median for EBITDA is -$20.3 million (2023), against an average of -$33.9 million.
  • The largest annual shift saw EBITDA grew 6.09% in 2024 before it plummeted 329.01% in 2025.
  • A 5-year view of EBITDA shows it stood at -$12.7 million in 2021, then plummeted by 48.41% to -$18.9 million in 2022, then dropped by 27.46% to -$24.1 million in 2023, then crashed by 57.07% to -$37.8 million in 2024, then crashed by 316.68% to -$157.7 million in 2025.
  • Per Business Quant, the three most recent readings for VKTX's EBITDA are -$157.7 million (Q4 2025), -$90.2 million (Q3 2025), and -$65.5 million (Q2 2025).